VBI Vaccines Inc. Share Price Toronto S.E.
Equities
VBV
CA91822J1030
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
4.82 CAD | -5.12% | -7.66% | -10.58% |
04-16 | VBI Vaccines Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
04-15 | North American Morning Briefing : Stock Futures -2- | DJ |
Sales 2024 * | 14.48M 19.78M 1.16B | Sales 2025 * | 34.12M 46.6M 2.72B | Capitalization | 16.32M 22.29M 1.3B |
---|---|---|---|---|---|
Net income 2024 * | -42M -57.36M -3.35B | Net income 2025 * | -25M -34.14M -2B | EV / Sales 2024 * | 1.13 x |
Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 0.48 x |
P/E ratio 2024 * |
-0.41
x | P/E ratio 2025 * |
-1.13
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.9% |
1 day | -5.12% |
Managers | Title | Age | Since |
---|---|---|---|
Jeff Baxter
CEO | Chief Executive Officer | 62 | 30/04/16 |
Nell Beattie
DFI | Director of Finance/CFO | 36 | 08/07/15 |
David Anderson
CTO | Chief Tech/Sci/R&D Officer | 54 | 05/05/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Vaughn Himes
BRD | Director/Board Member | 63 | 23/04/23 |
Steven Gillis
CHM | Chairman | 71 | 31/12/04 |
Jeff Baxter
CEO | Chief Executive Officer | 62 | 30/04/16 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+48.54% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- VBIV Stock
- VBV Stock